Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.
Enrollment in the 30,000-volunteer U.S. trial testing a Covid-19 vaccine from Pfizer and German partner BioNTech is more than 50 percent complete, according to a top Pfizer vaccine research and development scientist.
Acadia Pharmaceuticals is adding a novel pain portfolio to the company’s pipeline through the acquisition of Texas-based CerSci Therapeutics for $52.5 million.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
Moderna Inc. said an analysis of the early-stage data of the company’s experimental Covid-19 vaccine showed mRNA-1273 induced immune responses in older adults that were similar to younger participants.
VBI Vaccines Inc. said the company expected to begin human testing of two experimental Covid-19 vaccine candidates at the end of the 2020.
The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd. with conspiring with competitors to raise prices for generic drugs.
In this webinar, learn how diverse drug development companies with unique models of discovery, innovative drug modalities and non-traditional/natural product source material use phenotypic screening and profiling to understand their compounds’ disease impact.
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for Tricida’s experimental chronic kidney disease treatment veverimer.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
